Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

The specter of tariffs is likely to overshadow what was a positive quarter for J&J. The company’s adjusted earnings rose 2.2% ...

By Patrick Wingrove and Bhanvi Satija (Reuters) -Johnson & Johnson on Tuesday reported first-quarter revenue and profit above ...

As Fierce Pharma points out, patent expirations are a routine occurrence in the pharmaceutical world, but 2025 stands out for the unusually large number of drugs affected. Among the companies facing ...

By Patrick Wingrove and Bhanvi Satija (Reuters) -Johnson & Johnson on Tuesday reported first-quarter revenue and profit above ...

Johnson & Johnson (J&J) has announced that Stelara (ustekinumab) has been approved by the European Commission (EC) to treat ...

Alumis Inc. focuses on TYK2 inhibitors ESK-001 and A-005, with ESK-001 in Phase 3 for plaque psoriasis. Find out why ALMS ...

With recession concerns circulating in the market, Johnson & Johnson (JNJ) stock could stabilize many portfolios. Since its founding in ...

Goldman Sachs upgraded Johnson & Johnson (JNJ) from Neutral to Buy, citing underappreciated Innovative Medicine business and ...